H.R. 4369 · 117th Congress

National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing Act of 2021

Introduced on Jul 6, 2021 by Frank Pallone, Jr. (D-NJ-6). One cosponsor. Latest action (Oct 20, 2021): Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Stage
Passed one chamber
Introduced
Jul 6, 2021
Cosponsors
1
1 from the other party
Policy area
Health
Open in the Congress explorerCongress.govAlert me

Progress

The furthest stage the measure reached. Simple and concurrent resolutions do not go to the President.

  1. Introduced
  2. Reported by committee
  3. Passed one chamber
  4. 4Passed both chambers
  5. 5Sent to the President
  6. 6Became law

Official title

To amend the 21st Century Cures Act to provide for designation of institutions of higher education that provide research, data, and leadership on continuous manufacturing as National Centers of Excellence in Continuous Pharmaceutical Manufacturing, and for other purposes.

Subjects

  • Advanced technology and technological innovations
  • Congressional oversight
  • Department of Health and Human Services
  • Drug safety, medical device, and laboratory regulation
  • Food and Drug Administration (FDA)
  • Government information and archives
  • Health programs administration and funding
  • Health technology, devices, supplies
  • Higher education
  • Manufacturing
  • Prescription drugs
  • Product development and innovation
  • Research administration and funding
  • Research and development

Summary

By the Congressional Research Service (Passed House, Oct 19, 2021). Public domain.

National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing Act of 2021

This bill directs the Food and Drug Administration (FDA) to designate qualified institutions of higher education (or consortia of such institutions) as National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing and to provide grants to the centers. Each designated center must conduct research on advanced and continuous pharmaceutical manufacturing technologies and must share information from such research with the FDA. (Currently, most drug production involves batch manufacturing, which typically takes longer than continuous manufacturing processes.)

Sponsor and cosponsors

Cosponsors by party as of the day they signed on. Original cosponsors signed on the day of introduction.

Frank Pallone, Jr.D-NJ-6Sponsor

Republicans · 1

Roll calls

Recorded votes on the measure. Most measures move by voice vote or unanimous consent, which record no individual positions.

  1. On Motion to Suspend the Rules and Pass, as Amended
    Oct 19, 2021· House· Passage· Passed 368–56

History

Every action as published, oldest first. Roll calls link to how each member voted.

  1. Jul 6, 2021Introduced in House
  2. Jul 6, 2021Introduced in House
  3. Jul 6, 2021 · HouseReferred to the House Committee on Energy and Commerce.
  4. Jul 7, 2021 · HouseReferred to the Subcommittee on Health.
  5. Jul 15, 2021 · HouseSubcommittee Consideration and Mark-up Session Held.
  6. Jul 15, 2021 · HouseForwarded by Subcommittee to Full Committee (Amended) by Voice Vote .
  7. Jul 21, 2021 · HouseCommittee Consideration and Mark-up Session Held.
  8. Jul 21, 2021 · HouseOrdered to be Reported (Amended) by Voice Vote.
  9. Oct 19, 2021Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 117-151.
  10. Oct 19, 2021 · HouseReported (Amended) by the Committee on Energy and Commerce. H. Rept. 117-151.
  11. Oct 19, 2021 · HousePlaced on the Union Calendar, Calendar No. 111.
  12. Oct 19, 2021 · HouseMr. Pallone moved to suspend the rules and pass the bill, as amended.
  13. Oct 19, 2021 · HouseConsidered under suspension of the rules. (consideration: CR H5645-5647)
  14. Oct 19, 2021 · HouseDEBATE - The House proceeded with forty minutes of debate on H.R. 4369.
  15. Oct 19, 2021 · HouseAt the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
  16. Oct 19, 2021 · HouseConsidered as unfinished business. (consideration: CR H5662-5663)
  17. Oct 19, 2021Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 368 - 56 (Roll no. 318).(text: CR H5645-5647)House · Roll call 318
  18. Oct 19, 2021 · HouseOn motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 368 - 56 (Roll no. 318). (text: CR H5645-5647)House · Roll call 318
  19. Oct 19, 2021 · HouseMotion to reconsider laid on the table Agreed to without objection.
  20. Oct 19, 2021 · HouseThe title of the measure was amended. Agreed to without objection.
  21. Oct 20, 2021 · SenateReceived in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Committees

Committees and subcommittees the measure was referred to.

Agencies in its committees' jurisdiction

Analisa's mapping of committee jurisdiction to federal agencies; the bill may touch others, or none of these.

Sources and method

Every figure on this page traces to these records.

  • Bill status: bills and resolutions, sponsors, actions, subjects and CRS summaries (U.S. Government Publishing Office (GovInfo), from Congress.gov (Library of Congress))GovInfo Bill Status bulk data (Congress.gov; summaries by the Congressional Research Service) · data current to Oct 6, 2026 · loaded Oct 6, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Members of Congress, their terms, committees and identifiers (The @unitedstates project (from the Biographical Directory of the U.S. Congress, the House and the Senate))unitedstates/congress-legislators: legislators, committees and current committee membership · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: CC0 1.0 (public domain dedication)
  • House roll-call votes (Office of the Clerk, U.S. House of Representatives)Office of the Clerk, U.S. House of Representatives, roll-call vote records · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Senate roll-call votes and DW-NOMINATE scores (Voteview (UCLA Department of Political Science))Lewis, Jeffrey B., Keith Poole, Howard Rosenthal, Adam Boche, Aaron Rudkin, and Luke Sonnet (2026). Voteview: Congressional Roll-Call Votes Database. https://voteview.com/ · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Free to use with the required citation
  • Lobbying disclosures (LD-1 registrations, LD-2 quarterly reports, LD-203 contribution reports) (Clerk of the U.S. House of Representatives)Clerk of the House, Lobbying Disclosure Act filings (organizations only; lobbyists' names are not loaded) · data current to Oct 6, 2026 · loaded Oct 6, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Positions are shown only where a roll call recorded them; voice votes and unanimous consent record none.